This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brisse, S.
Right arrow Articles by Schmitz, F.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brisse, S.
Right arrow Articles by Schmitz, F.-J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2513-2516, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Association of Alterations in ParC and GyrA Proteins with Resistance of Clinical Isolates of Enterococcus faecium to Nine Different Fluoroquinolones

Sylvain Brisse,1,* Ad C. Fluit,1 Ulrich Wagner,2 Peter Heisig,3 Dana Milatovic,1 Jan Verhoef,1 Sybille Scheuring,2 Karl Köhrer,2 and Franz-Josef Schmitz1,2

Eijkman-Winkler Institute, Utrecht University, 3584 CX, Utrecht, The Netherlands,1 and Institute for Medical Microbiology and Virology, University Hospital Düsseldorf, D-40225 Düsseldorf,2 and Institute for Pharmaceutical Microbiology, University of Bonn, Bonn,3 Germany

Received 30 March 1999/Returned for modification 28 June 1999/Accepted 27 July 1999

The parC and gyrA genes of 73 ciprofloxacin-resistant and 6 ciprofloxacin-susceptible Enterococcus faecium clinical isolates were partly sequenced. Alterations in ParC and GyrA, possibly in combination with other resistance mechanisms, severely restricted the in vitro activities of the nine quinolones tested. For all isolates, clinafloxacin and sitafloxacin showed the best activities.


* Corresponding author. Mailing address: Eijkman-Winkler Institute, Utrecht University, AZU G04.614, Heidelberglaan 100, 3585 CX, Utrecht, The Netherlands. Phone: 31 30 250-7625. Fax: 31 30 254-1770. E-mail: sbrisse{at}lab.azu.nl.


Antimicrobial Agents and Chemotherapy, October 1999, p. 2513-2516, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Hummel, A. S., Hertel, C., Holzapfel, W. H., Franz, C. M. A. P. (2007). Antibiotic Resistances of Starter and Probiotic Strains of Lactic Acid Bacteria. Appl. Environ. Microbiol. 73: 730-739 [Abstract] [Full Text]  
  • Oyamada, Y., Ito, H., Inoue, M., Yamagishi, J.-i. (2006). Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis.. J Med Microbiol 55: 1395-1401 [Abstract] [Full Text]  
  • Oyamada, Y., Ito, H., Fujimoto, K., Asada, R., Niga, T., Okamoto, R., Inoue, M., Yamagishi, J.-i. (2006). Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol 55: 729-736 [Abstract] [Full Text]  
  • Leavis, H. L., Willems, R. J. L., Top, J., Bonten, M. J. M. (2006). High-Level Ciprofloxacin Resistance from Point Mutations in gyrA and parC Confined to Global Hospital-Adapted Clonal Lineage CC17 of Enterococcus faecium.. J. Clin. Microbiol. 44: 1059-1064 [Abstract] [Full Text]  
  • Brisse, S., Fussing, V., Ridwan, B., Verhoef, J., Willems, R. J. L. (2002). Automated Ribotyping of Vancomycin-Resistant Enterococcus faecium Isolates. J. Clin. Microbiol. 40: 1977-1984 [Abstract] [Full Text]  
  • Ackermann, G., Tang, Y. J., Rodloff, A. C., Silva, J. Jr, Cohen, S. H., Heisig, P. (2001). In vitro activity of sitafloxacin against Clostridium difficile. J Antimicrob Chemother 47: 722-724 [Full Text]